A PROSPECTIVE, RANDOMIZED MULTICENTER, OPEN-LABEL COMPARISON OF PREOPERATIVE TRASTUZUMAB EMTANSINE (T-DM1) WITH OR WITHOUT STANDARD ENDOCRINE THERAPY VS. TRASTUZUMAB WITH STANDARD ENDOCRINE THERAPY GIVEN FOR TWELVE WEEKS IN PATIENTS WITH OPERABLE HER2+/HR+ BREAST CANCER WITHIN THE ADAPT PROTOCOL.: